Smoking Status Influences Clinical Outcome in Collagenous Colitis.

BACKGROUND The relationship between clinical and histological parameters in collagenous colitis (CC) is poorly understood. Smoking is a risk factor for CC, whereas its impact on clinical activity and outcome is not well known. METHODS In a post hoc analysis of pooled data from two randomized controlled trials we assessed the association between demographic data (gender, age, smoking habits, family history of inflammatory bowel disease), clinical variables (duration of symptoms, mean number of stools/watery stools per day, abdominal pain, clinical remission) and histological data (thickness of the collagen band, inflammation of the lamina propria, total numbers of intraepithelial lymphocytes, degeneration). Moreover, we analysed the predictive value of baseline parameters for clinical outcome in a logistic regression model. RESULTS Pooled data were available from 202 patients with active CC, of whom 36% were current smokers, 29% former smokers and 35% non-smokers. Smoking status was associated with decreased ability to achieve clinical remission (current smokers vs non-smokers: odds ratio [OR] 0.31, 95% confidence interval [CI] 0.10-0.98, p = 0.045; former smokers vs non-smokers: OR 0.19, 95% CI 0.05-0.73, p = 0.016). Current smokers had an increased mean number of watery stools at baseline compared with non-smokers (p = 0.051) and increased mean number of watery stools per se was associated with decreased likelihood of obtaining clinical remission (OR 0.63, 95% CI 0.47-0.86, p = 0.003). Patient characteristics and histology at baseline had no association with clinical parameters and no predictive value for clinical outcome. CONCLUSION Smoking worsens clinical symptoms in CC and is associated with an increased number of watery stools and decreased likelihood of achieving clinical remission. There is no significant association between histology and clinical data.

[1]  Ashwin N. Ananthakrishnan,et al.  Epidemiology and risk factors for IBD , 2015, Nature Reviews Gastroenterology &Hepatology.

[2]  A. Öst,et al.  Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial , 2014, Gut.

[3]  K. Whelan,et al.  Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. , 2014, Journal of Crohn's & colitis.

[4]  A. Zinsmeister,et al.  The epidemiology of microscopic colitis in Olmsted County from 2002 to 2010: a population-based study. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[5]  M. Vieth,et al.  Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. , 2014, Gastroenterology.

[6]  D. Aust,et al.  Risk Factors for Symptom Relapse in Collagenous Colitis After Withdrawal of Short-term Budesonide Therapy , 2013, Inflammatory bowel diseases.

[7]  J. Bohr,et al.  Stable Incidence of Collagenous Colitis and Lymphocytic Colitis in Örebro, Sweden, 1999–2008: A Continuous Epidemiologic Study , 2013, Inflammatory bowel diseases.

[8]  J. Gisbert,et al.  Impact of Current Smoking on the Clinical Course of Microscopic Colitis , 2013, Inflammatory bowel diseases.

[9]  J. Gisbert,et al.  Epidemiological Risk Factors in Microscopic Colitis: A Prospective Case–Control Study , 2013, Inflammatory bowel diseases.

[10]  D. Aust,et al.  Microscopic colitis: Current status, present and future challenges: statements of the European Microscopic Colitis Group. , 2012, Journal of Crohn's & colitis.

[11]  E. Stylianou,et al.  Epigenetics: Concepts and relevance to IBD pathogenesis , 2012, Inflammatory bowel diseases.

[12]  L. Bianchi,et al.  Current and past cigarette smoking significantly increase risk for microscopic colitis , 2012, Inflammatory bowel diseases.

[13]  L. Munck,et al.  Microscopic colitis: clinical findings, topography and persistence of histopathological subgroups , 2011, Alimentary pharmacology & therapeutics.

[14]  J. Bohr,et al.  Is smoking a risk factor for collagenous colitis? , 2011, Scandinavian journal of gastroenterology.

[15]  J. Bohr,et al.  Health-related quality of life is impaired in active collagenous colitis. , 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[16]  J. Bohr,et al.  Defining clinical criteria for clinical remission and disease activity in collagenous colitis , 2009, Inflammatory bowel diseases.

[17]  J. Macdonald,et al.  Interventions for Treating Microscopic Colitis: A Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Review Group Systematic Review of Randomized Trials , 2009, The American Journal of Gastroenterology.

[18]  P. Lakatos,et al.  Smoking in inflammatory bowel diseases: good, bad or ugly? , 2007, World journal of gastroenterology.

[19]  M. Stolte,et al.  Long‐term follow‐up of collagenous colitis after induction of clinical remission with budesonide , 2005, Alimentary pharmacology & therapeutics.

[20]  L. Friedman,et al.  Collagenous colitis pathophysiologic considerations , 1991, Digestive Diseases and Sciences.

[21]  C. M. Edwards,et al.  `Microscopic colitis': classification and terminology , 2002, Histopathology.

[22]  K. Wang,et al.  Collagenous colitis: a clinicopathologic correlation. , 1987, Mayo Clinic proceedings.